CATHERINE MILLET: Open Payments
NPI 1740678317 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,587 in 84 payments from 16 companies in 2025. Trend: 2023 $2,134 · 2024 $1,824 · 2025 $1,587
Food & beverage: $1,587
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 11 | $293 |
| Galderma Laboratories, L.P. | 14 | $266 |
| ABBVIE INC. | 11 | $186 |
| Organon LLC | 10 | $138 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 11 | $135 |
| Novartis Pharmaceuticals Corporation | 3 | $82 |
| Arcutis Biotherapeutics, Inc. | 4 | $78 |
| Janssen Biotech, Inc. | 4 | $75 |
| Lilly USA, LLC | 4 | $71 |
| Amgen Inc. | 3 | $58 |
Products named: DUPIXENT, NEMLUVIO, SKYRIZI, VTAMA, Zoryve, TREMFYA, OTEZLA, TALTZ.
Industry payments across TX — which companies pay providers there.
